General Information (Narrative) (Details) (USD $)			0 Months Ended
Oct. 02, 2012	Mar. 15, 2013 Investment In iGlue	Oct. 02, 2012 Genetic Immunity, Inc.
Purchase Price (At Par Value)			$ 1.000
Fair Value Adjustment Of Shares			$ 25,074,621
Total Purchase Price	25,074,621		25,074,621
Investment in Common stock outstanding		2,884,986
Share warrants to purchase		3,000,000
Market Value Of Shares Outstading		$ 8,366,459

The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant